71,750 Shares in Royalty Pharma plc (NASDAQ:RPRX) Acquired by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC acquired a new stake in Royalty Pharma plc (NASDAQ:RPRX) in the third quarter, Holdings Channel.com reports. The firm acquired 71,750 shares of the biopharmaceutical company’s stock, valued at approximately $2,030,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Aurora Investment Counsel boosted its holdings in shares of Royalty Pharma by 1.0% in the third quarter. Aurora Investment Counsel now owns 50,441 shares of the biopharmaceutical company’s stock worth $1,427,000 after acquiring an additional 512 shares during the period. Xponance Inc. boosted its stake in Royalty Pharma by 1.9% in the 2nd quarter. Xponance Inc. now owns 31,704 shares of the biopharmaceutical company’s stock worth $836,000 after purchasing an additional 606 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Royalty Pharma by 32.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 655 shares in the last quarter. Values First Advisors Inc. increased its position in shares of Royalty Pharma by 7.6% during the third quarter. Values First Advisors Inc. now owns 10,412 shares of the biopharmaceutical company’s stock valued at $295,000 after buying an additional 738 shares during the period. Finally, Phillips Wealth Planners LLC lifted its holdings in shares of Royalty Pharma by 10.2% in the third quarter. Phillips Wealth Planners LLC now owns 8,733 shares of the biopharmaceutical company’s stock worth $246,000 after buying an additional 808 shares in the last quarter. Institutional investors own 54.35% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. The Goldman Sachs Group boosted their price objective on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. Finally, Citigroup lowered their price objective on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Royalty Pharma presently has an average rating of “Moderate Buy” and an average target price of $41.67.

Royalty Pharma Trading Down 0.9 %

Shares of Royalty Pharma stock opened at $26.43 on Tuesday. The company has a 50 day simple moving average of $27.15 and a two-hundred day simple moving average of $27.32. The firm has a market cap of $15.57 billion, a PE ratio of 13.69, a PEG ratio of 4.68 and a beta of 0.46. Royalty Pharma plc has a 1 year low of $25.10 and a 1 year high of $31.66. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date is Friday, November 15th. Royalty Pharma’s dividend payout ratio is currently 43.52%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.